Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.

ABSTRACT: Measles viruses derived from the live-attenuated Edmonton-B vaccine lineage are currently investigated as novel anti-cancer therapeutics. In this context, tumor specificity and oncolytic potency are key determinants of the therapeutic index. Here, we describe a systematic and comprehensive analysis of a recently developed post-entry targeting strategy based on the incorporation of microRNA target sites (miRTS) into the measles virus genome. We have established viruses with target sites for different microRNA species in the 3' untranslated regions of either the N, F, H, or L genes and generated viruses harboring microRNA target sites in multiple genes. We report critical importance of target-site positioning with proximal genomic positions effecting maximum vecto

SUBMITTER: Leber MF 

PROVIDER: S-EPMC6026446 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature